PUBLICATION

Advancing epilepsy treatment through personalized genetic zebrafish models

Authors
Griffin, A., Krasniak, C., Baraban, S.C.
ID
ZDB-PUB-160622-8
Date
2016
Source
Progress in brain research   226: 195-207 (Chapter)
Registered Authors
Baraban, Scott
Keywords
Antiepileptic, Drug discovery, Epilepsy, High throughput, Pharmacology, Zebrafish
MeSH Terms
  • Animals
  • Animals, Genetically Modified
  • Anticonvulsants/therapeutic use*
  • Disease Models, Animal
  • Epilepsy/drug therapy*
  • Epilepsy/genetics*
  • Humans
  • Mutation/genetics*
  • Zebrafish
  • Zebrafish Proteins/genetics
PubMed
27323944 Full text @ Prog. Brain Res.
Abstract
With an increase in the number of disease causing genetic mutations identified from epilepsy cohorts, zebrafish are proving to be an attractive vertebrate model for functional analysis of these allele variants. Not only do zebrafish have conserved gene functions, but larvae harboring mutations in identified human epileptic genes show spontaneous seizure activity and mimic the convulsive behavioral movements observed in humans. With zebrafish being compatible with medium to high-throughput screening, they are also proving to be a unique and powerful system for early preclinical drug screening, including novel target identification, pharmacology, and toxicology. Additionally, with recent advances in genomic engineering technologies, it is now possible to study the precise pathophysiology of patient-specific gene mutations in zebrafish. The following sections highlight how the unique attributes of zebrafish, in combination with genetic modifications, are continuing to transform our understanding of epilepsy and help identify personalized therapeutics for specific patient cohorts.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping